The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|January 28, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-02-03-2016
- Volume 12
- Issue 2
Onyx Scientific Announces Facility Expansion
Author(s)Pharmaceutical Technology Editors
Planned expansion at Onyx Scientific add laboratories, GMP suites, and storage space.
Advertisement
Onyx Scientific, a UK-based contract research organization and and small-scale API manufacturer, has announced an investment in an additional site located adjacent to its existing facility in North-East England to increase its laboratory facilities, GMP suites, and storage of GMP materials. In addition, the company has recruited several more chemists to support clients’ pre-clinical, development, and early-stage API manufacturing projects.
In 2015, the company grew its GMP space following an increase in demand for its small-scale API manufacturing services, according to a Jan. 28, 2016 press statement.
Established in 2000, the company provides clients with the production of API in up to 50 L–100 L equipment under current GMP regulations, and also offers earlier stage custom synthesis, lead optimization, and analytical services.
Source:
Articles in this issue
over 10 years ago
Is Consolidation Good for Pharma?over 10 years ago
Parenteral Packagers Focus on Security and Supply-Chain Transparencyover 10 years ago
Hermes Pharma Adds Hot Melt Coating Capabilityover 10 years ago
Novasep Adds Small-Scale Manufacturing Capability to US Facilityover 10 years ago
Vetter Completes Development and IT Facilityover 10 years ago
Adents, Siemens Team on Serialization Solutionover 10 years ago
FDA’s CDER Previews 2016 Guidance AgendaAdvertisement
Related to this article
The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Winners of the 2026 CPHI Pharma Awards Announced
2
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
3
Can Continuous Tableting End Scale-Up for Complex Oral Drugs?
4
Thermo Fisher Scientific Exhibits New Solutions and Expanded Capabilities at CPHI Milan
5